Shorla Oncology vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Shorla Oncology is a specialty pharma focused on oncology and rare/pediatric cancers; reformulates approved therapies to address drug shortages; raised $27M Series A in 2022; markets FDA-approved Enrylaze (asparaginase) in the US and EU.
About
Shorla Oncology is a specialty pharmaceutical company co-founded by Sharon Cunningham and Orlaith Ryan in 2019, headquartered in Cork, Ireland, with US operations in Westwood, Massachusetts. The company focuses on developing and commercializing oncology and rare disease drugs, with a particular emphasis on orphan and pediatric indications where treatment options are severely limited or where drug shortages threaten continuity of care. Shorla's approach centers on reformulating proven active pharmaceutical ingredients to improve administration, reduce toxicity, and ensure supply reliability for vulnerable patient populations.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.